Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade.

Published in: Journal of cancer research and clinical oncology (2024)

LSMM constitutes a novel biomarker for melanoma-specific survival in patients treated with adjuvant ICB.

Keyphrases